The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Progesterone

Progesterone

Progesterone is a key steroid hormone involved in the regulation of the female reproductive system.
It plays a crucial role in the menstrual cycle, pregnancy, and maintaining uterine function.
Progesterone research is essential for understanding hormonal imbalances, fertility, and related medical conditions.
PubCompare.ai offers a powerful AI-driven platform to streamline progesterone research by easily locating the best protocols from literature, preprints, and patents.
The platform enhances reproducibility and accuracy by comparing multiple studies side-by-side, helping researchers discover the optimal progesterone research methods and products to elevate their workfkow.
Explore PubCompare.ai today and take your progesterone research to new heights.

Most cited protocols related to «Progesterone»

A vaginal swab was collected using a cotton tipped swab (Puritan Medical Products Company, LLC Guilford, ME) wetted with ambient temperature physiological saline and inserted into the vagina of the restrained mouse. The swab was gently turned and rolled against the vaginal wall and then removed. Cells were transferred to a dry glass slide by rolling the swab across the slide. The slide was air dried and then stained with approximately 400 µL of stain (Accustain, Sigma-Aldrich, St. Louis, MO) for 45 seconds. The slides were rinsed with water, overlaid with a coverslip, and viewed immediately at 200× magnification under bright field illumination. The stage of the estrous cycle was determined based on the presence or absence of leukocytes, cornified epithelial, and nucleated epithelial cells according to Felicio, et al [9] (link).
When the female is in proestrus, mostly nucleated and some cornified epithelial cells are present. Some leukocytes may be present if the female is in early proestrus. As the stage of the cycle advances to estrus, mostly cornified epithelial cells are present. If the cycle is not interrupted by pregnancy, pseudopregnancy, or other phenomena, metestrus will begin. Metestrus is a brief stage when the corpora lutea form but fail to fully luteinize due to a lack of progesterone. The uterine lining will begin to slough and evidence of this is seen in the form of cornified eipithelial cells and polymorphonuclear leukocytes present in vaginal swabs. Some nucleated epithelia cells will also be present in late metestrus. Diestrus is the longest of the stages lasting more than 2 days. Vaginal swabs during diestrus show primarily polymorphonuclear leukocytes and a few epithelial cells during late diestrus. Leukocytes remain the predominant cell type having removed cellular debris. The cycle then repeats.
Full text: Click here
Publication 2012
Cells Corpus Luteum Diestrus Epithelial Cells Epithelioid Cells Estrous Cycle Estrus Gossypium Granulocyte Leukocytes Lighting Metestrus Mus Neoplasm Metastasis physiology Pregnancy Proestrus Progesterone Pseudocyesis Saline Solution Stains Uterus Vagina Vision Woman
A synthetic cDNA for human CYP17A1 was modified to delete residues 2–19, substitute the hydrophilic sequence 20RRCP23 (link) with 20AKKT23 (link), and add a C-terminal four histidine tag (fig. S6) before cloning into the pCWori+ plasmid and overexpression in E. coli JM109 cells. Protein was purified by nickel affinity, cation exchange, and size exclusion chromatography. Abiraterone was synthesized (Methods). Binding affinities were determined using a UV/vis spectral shift assay. Progesterone 17α-hydroxylation was evaluated using HPLC separation and UV detection. For crystallography, inhibitors were included throughout purification. Crystals were grown from CYP17A1 (30 mg/mL) complexed with inhibitor using hanging-drop vapor diffusion to equilibrate against 30% PEG 3350, 0.175 M Tris, pH 8.5, 0.30 M ammonium sulfate, and 3% glycerol. Diffraction data was collected and phased by molecular replacement. Iterative model building and refinement generated the final model. Substrates were docked using Surflex-Dock30 (link).
Publication 2011
abiraterone Biological Assay Cells Crystallography CYP17A1 protein, human Diffusion DNA, Complementary Escherichia coli Gel Chromatography Glycerin High-Performance Liquid Chromatographies Histidine Homo sapiens Hydroxylation inhibitors Nickel Plasmids polyethylene glycol 3350 Progesterone Proteins Sulfate, Ammonium Tromethamine
The overall objective of this study was to conduct a longitudinal assessment of the association of endogenous hormones with biomarkers of oxidative stress and antioxidant status during the menstrual cycle. There were four main objectives. The first was to study the intra-menstrual cycle variation of various measures of oxidative stress. This objective is intended to assess variation in several measures of oxidative stress during different phases of the menstrual cycle, including F2-8-isoprostanes in serum. Assessment of variation across individuals is planned. The second objective was to determine the relationship between specific reproductive hormone levels and oxidative stress during specific times in the menstrual cycle of premenopausal women. The panel of reproductive hormones in the blood that were of primary interest are oestradiol, progesterone, LH, FSH and sex hormone binding globulin (SHBG). The third objective was to examine the influence of external factors on both oxidative stress and hormone levels, and their interrelation. The study measured various biological factors that might influence oxidative stress, including serum concentration of certain antioxidant vitamin levels (retinoids, tocopherols, carotenoids and ascorbic acid). In addition, the study assessed other factors that might affect oxidative stress such as medication and supplement intake, cigarette smoking, alcohol consumption, dietary intake, physical activity and levels of stress. Lastly, the study was designed to evaluate the validity and reproducibility of the various biological markers included in the BioCycle study.
Publication 2009
Antioxidants Ascorbic Acid Biological Factors Biological Markers BLOOD Carotenoids Dietary Supplements Estradiol F2-Isoprostanes Hormones Menstrual Cycle Oxidative Stress Pharmaceutical Preparations Progesterone Reproduction Retinoids Serum Sex Hormone-Binding Globulin Tocopherol Vitamins Woman

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Animals Cells Clone Cells Corn oil Embryo Mus Pregnant Women Progesterone Pulse Rate SOX2 protein, human
A protocol with explicitly defined objectives, formal consensus development methods, criteria for participant identification and selection, and statistical methods was developed. The study was prospectively registered with the Core Outcome Measures in Effectiveness Trials (COMET) initiative (registration number 603 available online at www.comet-initiative.org/studies/details/603). The ethics board of the Academic Medical Center, Amsterdam, The Netherlands, advised that ethical approval was not required (reference number E2-172) because this project should be considered as service evaluation and development.
The target of the core outcome set was to capture important outcomes for individual studies, systematic reviews, and guidelines for preterm birth prevention in asymptomatic woman. For our purposes, preterm birth was defined as neonates born alive before 37 weeks of gestation.5 (link) An asymptomatic woman was defined as one without symptoms of preterm labor (e.g increased uterine contractions, menstrual cramps of backache, color change of vaginal discharge, prelabor rupture of membranes). Preventive treatment of preterm birth was defined as one started before any symptoms of preterm labor were present. This preventive strategy could be pharmacologic (e.g. progesterone, marine oils, probiotics) or non-pharmacologic (e.g. cerclage, pessary, lifestyle interventions and alternative therapies).
A Project Steering Committee was established to give guidance to the different phases of this project consisting of two obstetricians (Irene de Graaf, Khalid S. Khan), two neonatologists (Timo de Haan, Stephen Kempley), two midwives (Felipe Castro, Birgit van der Goes), two patient representatives (Aoife Ahern, Mandy Daly) and three methodologists with experience in formal consensus and/or core outcome set methods (James Duffy, Brent Opmeer, and Paula Williamson).
A systematic literature review was undertaken searching the Cochrane Pregnancy and Childbirth Group's (PCG) Trials Register.1 The Pregnancy and Childbirth Group register is maintained by monthly searches of the Cochrane Central Register of Controlled Trials and weekly searches of EMBASE and MEDLINE and hand-searches of 30 journal and conference proceedings (from January 1997 to January 2011). The register was searched utilizing the register’s codes for preterm birth. Two reviewers (S.M. and Z.A.) independently screened titles and abstracts. They critically reviewed the full text of selected studies and extracted reported outcomes. Any discrepancies were resolved by discussion. In addition, all delegates (n=168) of the First European Spontaneous Preterm Birth Congress (Svendborg, Denmark, May 24–25, 2014), mainly representing obstetricians and researchers, but also midwives, neonatologists and members of industry, were requested via e-mail to recommend potential outcomes.
Patient representatives and parents were invited through social media (Twitter and patient forums on Facebook) to participate in an online questionnaire to share their opinions regarding outcomes relevant to preterm birth. Members of patient organisations including the European foundation for the Care of Newborn Infants, their partner organizations, and parental forums of neonatal baby units were e-mailed by their own organization including an invitation for the online questionnaire through an electronic newsletter. Patients also contributed their opinions through in-person semistructured interviews conducted by one of the authors (J.v.t.H.).
The Project Steering Committee identified outcomes that were duplicated as a result of varied terminologies used by different stakeholders and for grouping closely related outcomes into overarching domains. This outcome inventory of 29 outcomes was entered into a Delphi process (Figure 1).
We used a two-round electronic Delphi survey design, a well-established method to elicit consensus based on an iterative process with anonymous consultation and with controlled feedback and quantified analysis of the responses.6 A priori we agreed the important methodological features for our Delphi process: [1] composition of the group; [2] anonymity; [3] how to assess the importance of outcomes; [4] method of feedback of results to participants; [5] how consensus would be reached; [6] how to assess possible attrition bias.
The setting for the Delphi survey was multinational involving stakeholders from middle- and high-income countries. A formal written invitation was e-mailed to all members of the Cochrane Pregnancy and Childbirth group (n=30), the Core Outcomes in Women’s Health initiative (n=77), the European Preterm Birth Congress (n=168), and the Global Obstetrics Network (n=237). Most members of these organizations are researchers (methodologists), obstetricians (mainly specialized in maternal fetal medicine) or neonatologists. The European foundation for the Care of Newborn Infants approached their members themselves, including their partner organizations in Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Mexico, the Netherlands, Norway, Poland, Portugal, Spain, Turkey, United Kingdom, and the United States. All midwifes from ‘Barts Health Nursing and Midwifery’ (n=132) and some midwifes of the School of Nursing and Midwifery (Galway, Ireland) and the Dutch Consortium for Healthcare Evaluation in Obstetrics and Gynaecology were approached. With this approach we aimed to targeted midwifes who were active in research (50%) and midwifes who were not active in research (50%). In total 337 obstetricians, 152 midwives, 174 researchers, 75 neonatologists, and an unknown number of parents (through the previously mentioned patient organizations) were invited.
We used LimeSurvey for the Delphi survey. The survey was piloted first by eight people representing every stakeholder group. No changes were needed after the pilot. The official survey had a closing date of 5 weeks after the date of invitation for every Delphi round. An e-mail reminder was sent to participants on days 7, 14, 21, and 28. Nonresponders in the first round were not invited to participate in the subsequent round.
Participants were asked to rate the importance of each outcome on a 9-point Likert scale anchored between 1 (‘limited importance’) and 9 (‘critical importance’). The scale is recommended by the Grading of Recommendations Assessment, Development and Evaluation working group: 1–3: limited importance; 4–6: important but not critical; 7–9: critical.7 (link) Participants were invited to recommend additional potential outcomes for consideration at the end of the survey using free-text responses.
The individual, stakeholder group and total results from the first round were relayed back to participants by e-mail; the individual responses directly after filling in the first round questionnaire, the stakeholder group, and total group responses were fed back anonymously 1 day prior to the invitation to the second round of the Delphi survey. Furthermore, participants of the second survey were able to see the mean value of the total group responses from the first Delphi round while completing the survey. Participants were asked to score all the individual outcomes again using the same 9-point Likert scale. No outcomes were excluded in this round to ensure a holistic approach to scoring in round 2.
The Delphi survey responses were analyzed using SPSS version 21.0. For each outcome the median and interquartile range were calculated. Frequency tables of all scores were generated, as well as boxplots for visualization (that were used to relay back the whole and stakeholder group responses). We defined consensus a priori. Core outcomes required at least 70% of participants in each stakeholder group scoring the outcome as ‘critical’ and less than 15% of participants in each stakeholder group scoring the outcome as ‘limited importance’.8 (link) Outcomes which should not be included in a core outcome set required at least 70% of participants in each stakeholder group scoring the outcome as ‘limited importance’ and less than 15% of participants in each stakeholder group scoring the outcome as ‘critical’. If outcomes did not meet either criteria they were classified as outcomes with no consensus. Attrition bias (e.g. a selective group did not respond to the second round of the survey or a selective group participated in the consultation meeting) was assessed by 1) comparing the distribution of median first round scores across the outcomes for those not participating in the second round with those who did; and 2) comparing the distribution of median round 2 scores across the outcomes for those participating in the consultation meeting compared with those who did not.
The final phase of the study was a face-to-face consultation meeting with participants of the Delphi exercise representing all stakeholder groups (Washington, DC, November 9, 2014). This meeting was organized within a meeting for a prospective individual participant data analysis project for studies on the use of pessary in the prevention of preterm birth in asymptomatic women. Eleven participants of this prospective individual patient data project did also took part in the Delphi survey earlier. They mainly represented the stakeholder groups of obstetricians and methodologists. Representatives from the other stakeholder groups (parents, midwives and neonatologists), who were living close to the location of the consultation meeting, were invited for this consultation meeting as well. In total 23 obstetricians, 10 researchers, two neonatologists, two patient representatives, and one midwife were invited to attend this meeting. Information material on the purpose of the consultation meeting and the Delphi round 2 results were sent to participants before the meeting. A plenary presentation on the Delphi survey outcomes was complemented by small group sessions (mixed groups) where participants expressed their views on the candidate outcomes. Only outcomes that did not reach full consensus in the Delphi exercise were presented to the attendees of the meeting with an anonymous voting using electronic touchpads. Consensus in the consultation meeting required a majority of 70% of participants from each stakeholder group approving an individual outcome as ‘critical’ according to the 1–9 Likert scale. With the permission of the participants the consultation meeting was recorded.
Publication 2016
Alternative Therapies Back Pain Childbirth Comet Assay Dysmenorrhea Europeans Face Fetal Membranes, Premature Rupture Genetic Code Infant Infant, Newborn Marines Midwife Neonatologists Obstetrician Oils Parent Patient Representatives Patients Pessaries Pregnancy Premature Birth Premature Obstetric Labor Probiotics Progesterone Tooth Attrition Uterine Contraction Woman

Most recents protocols related to «Progesterone»

Example 2

157.3 mg of progesterone and 75.2 mg of 4-formylbenzeneboronic acid were weighed and mixed, 3 ml of a methanol-ethanol-water (volume ratio=1:1:1) mixed solvent was added and stirred at 70° C. for 30 min until a completely clear solution was obtained, then the solution was allowed to stand at room temperature for 4 days to volatilize the solvent and precipitate crystals, and a cocrystal of progesterone was obtained after filtering and drying. The obtained cocrystal was subjected to single-crystal X-ray diffraction analysis. Its crystal data and structural parameters are shown in Table 1, indicating that the obtained crystal is a progesterone-4-formylbenzeneboronic acid cocrystal.

Full text: Click here
Patent 2024
Acids Crystallography, X-Ray Ethanol Methanol Progesterone Radiography Solvents
Not available on PMC !

Example 8

The progesterone monomer and the cocrystals of progesterone obtained in Examples 1-6 were subjected to dynamic vapour sorption analysis. The nitrogen flow rate was 200 ml/min, and the relative humidity, varied in a stepped manner by a change of 10%, increased from 20% to 80%, and then dropped to 0%. The water sorption kinetic curves at 25° C. were determined, and the results are shown in FIGS. 4, 1-4, 2-4 and 3-4. During the whole process, the change in relative mass of progesterone is less than 0.2%, indicating that progesterone is non-hygroscopic, and will neither absorb water nor be dehydrated when exposed to an environment with a certain humidity level. The changes in relative mass of the cocrystals of progesterone were also less than 0.2%, indicating that the obtained cocrystals of progesterone maintain the non-hygroscopic property of progesterone, and meet the basic requirements for a medicine.

Full text: Click here
Patent 2024
Figs Humidity Kinetics Nitrogen Pharmaceutical Preparations Progesterone

Example 3

157.2 mg of progesterone and 105.0 mg of 3-nitrophthalic acid were weighed and mixed, 3 ml of an ethanol-water (volume ratio=1:1) mixed solvent was added and stirred at 75° C. for 45 min until a completely clear solution was obtained, then the solution was allowed to stand at room temperature for 5 days to volatilize the solvent and precipitate crystals, and a cocrystal of progesterone was obtained after filtering and drying. The obtained cocrystal was subjected to single-crystal X-ray diffraction analysis. Its crystal data and structural parameters are shown in Table 1, indicating that the obtained crystal is a progesterone-3-nitrophthalic acid cocrystal.

Full text: Click here
Patent 2024
Acids Crystallography, X-Ray Ethanol Progesterone Radiography Solvents

Example 2

In an exemplary embodiment, a capsule is provided containing a fill material comprising:

TABLE 3
Ingredient%mg/CapsuleFunction
Ultra-micronized30.77200.00Active
Progesterone
Medium Chain65.93428.55Solubilizing Agent
Triglyceride
(MIGLYOL 812 or
equivalent)
Lauroyl polyoxyl-32-3.0019.50Suspending Agent
glycerides
(GELUCIRE 44/14 or
equivalent)
Butylated0.031.95Antioxidant
Hydroxytoluene
Total100650

In various embodiments, amounts of MIGLYOL may be present in a range from about 35-95% by weight; GELUCIRE 44/14 from about 0.5-30% by weight; and BHT from about 0.01-0.1% by weight.

Full text: Click here
Patent 2024
Antioxidants Capsule gelucire 44-14 Glycerides miglyol 812 Progesterone Suspending Agents Triglycerides

Example 8

Bioavailability Assessment—Fed

The procedures for determining bioavailability under fasted conditions are repeated except that subjects are administered a single 200 mg dose of either test product (T) or reference product (R) immediately following a high fat meal, for example, within 30 minutes of dosing. Blood is collected pre-dose and post-dose. Pre-dose samples are collected at approximately −01.00, −00.50, and 00.00 hours. Post-dose samples are collected at approximately 01.00, 02.00, 03.00, 04.00, 05.00, 06.00, 07.00, 08.00, 09.00, 10.00, 12.00, 18.00, 24.00, 36.00 and 48.00 hours. Standard meals are provided at 04.00, 09.00, 13.00, 25.00, 29.00, 33.00 and 37.00 hours post-dose. Pharmacokinetic measurements are assessed including Cmax, AUC and optionally Tmax. Bioavailability of the test product (T) in reference to the reference product is assessed. The effect of food on the comparative bioavailability of the test product (T) and the reference product (R) are also assessed.

Full text: Click here
Patent 2024
BLOOD Food Progesterone

Top products related to «Progesterone»

Sourced in United States, Germany, United Kingdom, Canada, France, Sao Tome and Principe, Macao, Japan, Italy, Brazil, China, Netherlands
Progesterone is a steroid hormone that plays a crucial role in the female reproductive system. It is a key component in the regulation of the menstrual cycle and supports the maintenance of pregnancy. Progesterone is commonly used in various lab equipment and scientific research applications.
Sourced in United States, Germany, France, United Kingdom, Spain, Canada, Japan
Putrescine is a chemical compound that is used as a building block in various laboratory experiments and applications. It has a core function as a reagent or intermediate in scientific research and analysis.
Sourced in United States, Germany, United Kingdom, China, France, Canada, Italy, Sao Tome and Principe, Japan, Switzerland, Macao, Israel, Australia, Spain, Austria, Sweden, Poland, Denmark, New Zealand, Belgium, Portugal, Ireland, Netherlands, Brazil, Colombia, India, Morocco, Argentina
Insulin is a lab equipment product designed to measure and analyze insulin levels. It provides accurate and reliable results for research and diagnostic purposes.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Germany, United Kingdom, Japan, Sao Tome and Principe, China, France, Macao, Switzerland, Israel, Belgium, Hungary, Canada, Italy
17β-estradiol is a natural estrogen hormone produced by the ovaries, adrenal glands, and other tissues in the body. It is a key component in various laboratory and research applications, serving as a substrate, reference standard, or analytical tool for the study of estrogen-related processes and pathways.
Sourced in Germany, France, China, Belgium
Progynova is a laboratory equipment product manufactured by Bayer. It is a device used for the analysis and measurement of progesterone levels in biological samples. The core function of Progynova is to provide accurate and reliable results for progesterone testing in research and clinical settings.
Sourced in United States, Germany, United Kingdom, France, Switzerland, China, Japan, Israel, India, Macao, Sweden, Canada, Italy, Belgium
Sodium selenite is a chemical compound that serves as a source of the essential trace element selenium. It is a white crystalline solid that is commonly used in various laboratory applications, including as a nutritional supplement, antioxidant, and in the production of specialized materials.
Sourced in United States, Germany, France, United Kingdom, Japan, China, Austria, Macao, Israel, Italy, Switzerland, Canada, Sao Tome and Principe, Australia, Poland, Sweden, Argentina
Transferrin is a laboratory product used as a critical component in cell culture media. It is a glycoprotein that plays a key role in the transport and delivery of iron to cells. Transferrin functions to bind and carry iron ions, facilitating their uptake and utilization by cells in vitro.
Sourced in United States, Germany, United Kingdom, Italy, Australia, Sao Tome and Principe, Canada, Czechia, Belgium
Estradiol is a laboratory reagent used for the measurement and detection of the estrogen hormone estradiol in biological samples. It is a commonly used compound in various analytical techniques, such as immunoassays and chromatographic methods, to quantify estradiol levels in research and clinical settings.
Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Denmark, Israel, Macao, Ireland, Netherlands, Austria, Hungary, Holy See (Vatican City State), Sweden, Brazil, Argentina, India, Poland, Morocco, Czechia
DMEM/F12 is a cell culture medium developed by Thermo Fisher Scientific. It is a balanced salt solution that provides nutrients and growth factors essential for the cultivation of a variety of cell types, including adherent and suspension cells. The medium is formulated to support the proliferation and maintenance of cells in vitro.

More about "Progesterone"

Progesterone, a crucial steroid hormone, plays a vital role in the regulation of the female reproductive system.
It is essential for the menstrual cycle, pregnancy maintenance, and uterine function.
Understanding the role of progesterone is crucial for addressing hormonal imbalances, fertility issues, and related medical conditions.
Researchers can leverage the power of PubCompare.ai, an AI-driven platform, to streamline their progesterone research by easily locating the best protocols from literature, preprints, and patents.
The platform enhances reproducibility and accuracy by allowing side-by-side comparisons of multiple studies, helping researchers discover the optimal progesterone research methods and products to elevate their workflow.
Exploring PubCompare.ai can unlock new possibilities in progesterone research, enabling researchers to delve deeper into topics related to P4, putrescine, insulin, FBS, 17β-estradiol, Progynova, sodium selenite, transferrin, estradiol, and DMEM/F12.
By harnessing the insights gained from this powerful platform, researchers can take their progesterone research to new heights and unlock groundbreaking discoveries.